Steph & Co. Sells 637 Shares of Avantor, Inc. (NYSE:AVTR)

Steph & Co. cut its stake in shares of Avantor, Inc. (NYSE:AVTR) by 3.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,057 shares of the company’s stock after selling 637 shares during the period. Steph & Co.’s holdings in Avantor were worth $338,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. UMB Bank n.a. bought a new position in shares of Avantor in the third quarter worth approximately $49,000. Nisa Investment Advisors LLC increased its stake in Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares in the last quarter. GAMMA Investing LLC raised its holdings in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after acquiring an additional 1,285 shares during the period. Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after acquiring an additional 3,700 shares in the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in shares of Avantor in the third quarter valued at about $139,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Price Performance

NYSE:AVTR opened at $21.82 on Thursday. The firm has a market capitalization of $14.85 billion, a price-to-earnings ratio of 47.43, a PEG ratio of 3.42 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The business has a 50 day simple moving average of $21.49 and a 200-day simple moving average of $23.36. Avantor, Inc. has a 1 year low of $19.59 and a 1 year high of $28.00.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Barclays decreased their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company lowered their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Robert W. Baird cut their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. UBS Group decreased their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $34.00 price objective on shares of Avantor in a research report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.69.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.